Intelligent Bio Solutions (Nasdaq: INBS) completes usability study for FDA 510(k)
Rhea-AI Filing Summary
Intelligent Bio Solutions Inc. reported completion of a Usability Study for its Intelligent Fingerprinting Drug Screening System, supporting an FDA 510(k) submission for U.S. market clearance to detect the opiate codeine. The study, run with CenExel Clinical Research, followed FDA guidance and ICH GCP standards.
The study evaluated how easily workplace operators can be trained to use the system; 15 operators with no specialist laboratory background successfully participated, reinforcing that the system can be administered by non-specialists. This Usability Study is part of a broader 510(k) program that also includes cut-off, method comparison, interference, precision and penetration testing. The company states it remains on track to submit its 510(k) package in calendar H2 2026 as it moves toward planned entry into the multi-billion-dollar U.S. drug screening market.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Usability study participants: 15 operators
Planned 510(k) submission timing: H2 2026
Result time: under ten minutes
3 metrics
Usability study participants
15 operators
Number of operators in the Usability Study with no specialist background
Planned 510(k) submission timing
H2 2026
Company states it remains on track to submit its 510(k) package in calendar H2 2026
Result time
under ten minutes
System delivers workplace drug screening results in under ten minutes
Key Terms
FDA 510(k) submission, Usability Study, ICH GCP (International Council for Harmonisation Good Clinical Practice), Intelligent Fingerprinting Drug Screening System
4 terms
FDA 510(k) submission regulatory
"supporting its FDA 510(k) submission for U.S. market clearance"
An FDA 510(k) submission is a regulatory filing to show a new medical device is sufficiently similar to an already-approved device so it can be marketed in the U.S. without undergoing the most extensive premarket review. For investors, 510(k) clearance is a key milestone that reduces regulatory uncertainty and shortens time to sales—think of it as proving a new product is close enough to an established model to be sold without rebuilding trust from scratch.
Usability Study technical
"announced the completion of its Usability Study for the Intelligent Fingerprinting"
A usability study is a structured test where real or representative users try a product, website, app, device, or process while observers record how easily they complete tasks, where they struggle, and what they misunderstand. Think of it like watching someone drive a new car model to spot confusing controls; the results show how likely customers are to adopt, keep using, or pay for the offering, and they can affect product development costs, time to market, regulatory compliance, and revenue projections.
ICH GCP (International Council for Harmonisation Good Clinical Practice) medical
"following FDA guidance and ICH GCP (International Council for Harmonisation Good Clinical Practice)"
Intelligent Fingerprinting Drug Screening System technical
"Usability Study for the Intelligent Fingerprinting Drug Screening System, supporting its"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Intelligent Bio Solutions (INBS) announce regarding its drug screening system?
Intelligent Bio Solutions announced completion of a Usability Study for its Intelligent Fingerprinting Drug Screening System, supporting an FDA 510(k) submission for U.S. clearance to detect the opiate codeine, using non-specialist operators in a workplace-style setting.
How many operators were involved in INBS’s usability study and what was their background?
The usability study included 15 operators who were not required to have specialist laboratory knowledge or prior experience with the system. The results support that the device can be used accurately by typical workplace personnel rather than trained laboratory staff.
How does the usability study fit into INBS’s FDA 510(k) program?
The Usability Study is one component of a broader FDA 510(k) submission program that also includes a Cut-off Study, Method Comparison Study, Interference Study, precision testing and penetration testing, all aimed at securing U.S. market clearance for the codeine test.
When does Intelligent Bio Solutions (INBS) plan to submit its 510(k) package?
Intelligent Bio Solutions states it remains on track to submit its 510(k) package in calendar H2 2026. This timing aligns with its progress toward planned entry into the multi-billion-dollar U.S. drug screening market for workplace testing.
What market opportunity is INBS targeting with its fingerprint drug screening system?
The company is progressing toward planned entry into the multi-billion-dollar U.S. drug screening market. Its Intelligent Fingerprinting Drug Screening System is designed for rapid, non-invasive workplace testing for substances including opiates, cocaine, methamphetamine and cannabis.
What are key features of INBS’s Intelligent Fingerprinting Drug Screening System?
The system uses fingerprint sweat analysis for non-invasive testing, with sample collection in seconds and results in under ten minutes. It targets recent use of drugs commonly found in workplaces and is designed as a hygienic, cost-effective solution for safety-critical industries.